Biomarkers in Samples From Young Patients With Soft Tissue Sarcoma
NCT ID: NCT01342783
Last Updated: 2016-05-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
20 participants
OBSERVATIONAL
2011-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
PURPOSE: This research trial is studying biomarkers in samples from young patients with soft tissue sarcoma.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Studying Genes in Tissue Samples From Younger and Adolescent Patients With Soft Tissue Sarcomas
NCT01567046
Biomarkers in Tissue Samples From Patients With Ewing Sarcoma
NCT01480518
Protein Expression in Samples From Young Patients With Rhabdomyosarcoma
NCT01426945
Studying Genes in Samples From Younger Patients With Rhabdomyosarcoma
NCT01585376
Biomarker in Tissue Samples From Patients With Ewing Sarcoma
NCT01365949
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
* To identify the key components of driver pathways of primary and secondary soft tissue sarcomas.
* To perform the next-generation sequencing on primary versus normal on undifferentiated sarcomas.
OUTLINE: Genomic DNA and RNA samples from undifferentiated sarcoma tumors are analyzed by next-generation sequencing for somatic mutations. Normal matched lymphocytes and tissue are also analyzed.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
RETROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
DNA analysis
RNA analysis
mutation analysis
nucleic acid sequencing
laboratory biomarker analysis
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Banked childhood samples from the COG-D9902 soft tissue sarcoma biology and banking study
* Rhabdomyosarcoma, NOS
PATIENT CHARACTERISTICS:
* Not specified
PRIOR CONCURRENT THERAPY:
* Not specified
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Cancer Institute (NCI)
NIH
Children's Oncology Group
NETWORK
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Poul Sorensen, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
British Columbia Cancer Agency
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
COG-ARST11B2
Identifier Type: OTHER
Identifier Source: secondary_id
NCI-2011-02853
Identifier Type: REGISTRY
Identifier Source: secondary_id
ARST11B2
Identifier Type: OTHER
Identifier Source: secondary_id
ARST11B2
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.